Genmab A/S said Wednesday it is winding down its anti-CD4 development program for rheumatoid arthritis after initial Phase II trial results showed no significant difference in American College of Rheumatology scores for patients who received placebo vs. those treated with HuMax-CD4. (BioWorld Today) Read More
